New York, NY — January 29, 2026 — HITLAB today announced a strategic partnership with Jeeva Clinical Trials, a U.S.-based digital research platform provider delivering a human-centric, AI-native eClinical cloud for decentralized and hybrid clinical trials.

As clinical research continues to shift toward distributed models, sponsors and CROs face growing complexity in deploying AI-enabled infrastructure that is operationally sound, scalable, and accessible to patients. This partnership brings together Jeeva’s unified eClinical platform and HITLAB’s independent research, validation, and market development expertise to support responsible adoption across the life sciences ecosystem.

Jeeva’s platform enables automated clinical trial workflows and remote participation across multiple therapeutic areas, including oncology and rare diseases. Through this collaboration, HITLAB will support Jeeva’s U.S. growth by independently assessing platform usability and operational fit, strengthening evidence communication, and facilitating strategic engagement with biopharma sponsors, CROs, and investors.

“The next phase of clinical research depends on AI-native platforms that are not only technically advanced, but also trustworthy, usable, and aligned with real-world research operations,” said Stan Kachnowski, PhD, Chair and Co-Founder of HITLAB. “This partnership reflects HITLAB’s commitment to independently evaluating emerging research infrastructure while helping high-potential platforms responsibly scale in the U.S. market.”

HITLAB will also work with Jeeva to synthesize existing platform insights and customer experiences into clear, publishable materials and market-facing narratives, which wil be shared during HITLAB’s May 2026 Innovators Summit in New York City.

“Decentralized trials require connected infrastructure that is both operationally rigorous and patient-centered,” said Harsha Rajasimha, PhD, Founder and CEO of Jeeva Clinical Trials. “Working with HITLAB allows us to independently validate how our platform performs in real-world research environments while accelerating engagement with sponsors and CROs seeking integrated, AI-enabled solutions that reduce cost and complexity.”